PYC Therapeutics Limited (PYC.AX)
AUD 1.08
(8.0%)
AUD 1.08
(8.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -37.72 Million AUD | -65.54% |
| 2023 | -22.78 Million AUD | -64.39% |
| 2022 | -13.86 Million AUD | 21.97% |
| 2021 | -17.76 Million AUD | -160.44% |
| 2020 | -6.82 Million AUD | -67.22% |
| 2019 | -4.07 Million AUD | 45.12% |
| 2018 | -7.43 Million AUD | -281.07% |
| 2017 | -1.95 Million AUD | 50.97% |
| 2016 | -3.97 Million AUD | -33.0% |
| 2015 | -2.99 Million AUD | 8.17% |
| 2014 | -3.25 Million AUD | 5.29% |
| 2013 | -3.43 Million AUD | 11.91% |
| 2012 | -3.9 Million AUD | -8.3% |
| 2011 | -3.6 Million AUD | 21.16% |
| 2010 | -4.57 Million AUD | -1.82% |
| 2009 | -4.49 Million AUD | -0.16% |
| 2008 | -4.48 Million AUD | -15.31% |
| 2007 | -3.88 Million AUD | 2.58% |
| 2006 | -3.99 Million AUD | -151.46% |
| 2005 | -1.58 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -37.72 Million AUD | -65.54% |
| 2024 Q2 | -15.09 Million AUD | 0.0% |
| 2024 Q4 | -22.63 Million AUD | 0.0% |
| 2023 Q4 | -6.55 Million AUD | 0.0% |
| 2023 FY | -22.78 Million AUD | -64.39% |
| 2023 Q2 | -16.23 Million AUD | 0.0% |
| 2022 FY | -13.86 Million AUD | 21.97% |
| 2022 Q4 | -7.44 Million AUD | 0.0% |
| 2022 Q2 | -6.41 Million AUD | 0.0% |
| 2021 FY | -17.76 Million AUD | -160.44% |
| 2021 Q2 | -7.36 Million AUD | 0.0% |
| 2021 Q4 | -10.39 Million AUD | 0.0% |
| 2020 Q4 | -4.72 Million AUD | 0.0% |
| 2020 FY | -6.82 Million AUD | -67.22% |
| 2020 Q2 | -2.1 Million AUD | 0.0% |
| 2019 Q4 | -3.13 Million AUD | 0.0% |
| 2019 FY | -4.07 Million AUD | 45.12% |
| 2019 Q2 | -945.55 Thousand AUD | 0.0% |
| 2018 Q2 | -3.52 Million AUD | 0.0% |
| 2018 FY | -7.43 Million AUD | -281.07% |
| 2018 Q4 | -3.91 Million AUD | 0.0% |
| 2017 Q4 | -1.49 Million AUD | 0.0% |
| 2017 FY | -1.95 Million AUD | 50.97% |
| 2017 Q2 | -458.13 Thousand AUD | 0.0% |
| 2016 Q2 | -745.31 Thousand AUD | 0.0% |
| 2016 FY | -3.97 Million AUD | -33.0% |
| 2016 Q4 | -3.23 Million AUD | 0.0% |
| 2015 Q2 | -134.91 Thousand AUD | 0.0% |
| 2015 FY | -2.99 Million AUD | 8.17% |
| 2015 Q4 | -2.85 Million AUD | 0.0% |
| 2014 Q2 | -393.17 Thousand AUD | 0.0% |
| 2014 Q4 | -2.86 Million AUD | 0.0% |
| 2014 FY | -3.25 Million AUD | 5.29% |
| 2013 Q3 | -859.9 Thousand AUD | 25.74% |
| 2013 Q2 | -1.15 Million AUD | -18.62% |
| 2013 Q1 | -976.13 Thousand AUD | 0.0% |
| 2013 FY | -3.43 Million AUD | 11.91% |
| 2013 Q4 | -2.28 Million AUD | -165.35% |
| 2012 Q4 | -976.13 Thousand AUD | 0.0% |
| 2012 Q2 | -976.13 Thousand AUD | -8.3% |
| 2012 Q3 | -976.13 Thousand AUD | 0.0% |
| 2012 FY | -3.9 Million AUD | -8.3% |
| 2012 Q1 | -901.29 Thousand AUD | 0.0% |
| 2011 FY | -3.6 Million AUD | 21.16% |
| 2011 Q2 | -901.29 Thousand AUD | 21.16% |
| 2011 Q3 | -901.29 Thousand AUD | 0.0% |
| 2011 Q4 | -901.29 Thousand AUD | 0.0% |
| 2011 Q1 | -1.14 Million AUD | 0.0% |
| 2010 Q1 | -1.12 Million AUD | 0.0% |
| 2010 FY | -4.57 Million AUD | -1.82% |
| 2010 Q4 | -1.14 Million AUD | 0.0% |
| 2010 Q2 | -1.14 Million AUD | -1.82% |
| 2010 Q3 | -1.14 Million AUD | 0.0% |
| 2009 Q1 | -1.12 Million AUD | 0.0% |
| 2009 Q2 | -1.12 Million AUD | -0.16% |
| 2009 Q3 | -1.12 Million AUD | 0.0% |
| 2009 FY | -4.49 Million AUD | -0.16% |
| 2009 Q4 | -1.12 Million AUD | 0.0% |
| 2008 Q4 | -1.12 Million AUD | 0.0% |
| 2008 FY | -4.48 Million AUD | -15.31% |
| 2008 Q1 | -972.16 Thousand AUD | 0.0% |
| 2008 Q2 | -1.12 Million AUD | -15.31% |
| 2008 Q3 | -1.12 Million AUD | 0.0% |
| 2007 Q3 | -972.16 Thousand AUD | 0.0% |
| 2007 FY | -3.88 Million AUD | 2.58% |
| 2007 Q4 | -972.16 Thousand AUD | 0.0% |
| 2007 Q2 | -972.16 Thousand AUD | 2.58% |
| 2007 Q1 | -997.86 Thousand AUD | 0.0% |
| 2006 Q4 | -997.86 Thousand AUD | 0.0% |
| 2006 Q2 | -997.86 Thousand AUD | -151.46% |
| 2006 Q3 | -997.86 Thousand AUD | 0.0% |
| 2006 FY | -3.99 Million AUD | -151.46% |
| 2006 Q1 | -396.83 Thousand AUD | 0.0% |
| 2005 Q3 | -396.83 Thousand AUD | 0.0% |
| 2005 Q2 | -396.83 Thousand AUD | 0.0% |
| 2005 FY | -1.58 Million AUD | 0.0% |
| 2005 Q4 | -396.83 Thousand AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | -601.05% |
| Acrux Limited | -5.8 Million AUD | -550.438% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | -171.999% |
| BTC Health Limited | 1.05 Million AUD | 3674.896% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | -201.084% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 10.866% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 205.862% |
| Biome Australia Limited | -1.67 Million AUD | -2158.733% |
| Hexima Limited | -933.87 Thousand AUD | -3939.673% |
| Immutep Limited | -39.89 Million AUD | 5.441% |
| Memphasys Limited | -4.44 Million AUD | -749.285% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 124.017% |
| Noxopharm Limited | -3.57 Million AUD | -954.337% |
| Prescient Therapeutics Limited | -8.23 Million AUD | -357.941% |
| Race Oncology Limited | -13.81 Million AUD | -172.99% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 21.322% |
| Starpharma Holdings Limited | -8.16 Million AUD | -362.038% |
| Tissue Repair Ltd | -4.13 Million AUD | -811.659% |
| Biotron Limited | -3.43 Million AUD | -997.778% |
| Alterity Therapeutics Limited | -19.12 Million AUD | -97.273% |
| CSL Limited | 2.64 Billion AUD | 101.428% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 641.682% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -2499.526% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -1465.903% |
| Zelira Therapeutics Limited | -36.56 Million AUD | -3.163% |
| Patrys Limited | -3.53 Million AUD | -965.946% |
| Orthocell Limited | -7.18 Million AUD | -425.353% |
| Imugene Limited | -149.68 Million AUD | 74.796% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | -491.658% |
| Cynata Therapeutics Limited | -9.74 Million AUD | -287.137% |
| Arovella Therapeutics Limited | -8.74 Million AUD | -331.343% |
| Nanollose Limited | -1.15 Million AUD | -3161.883% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -2197.795% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 11736.103% |
| Amplia Therapeutics Limited | -4.5 Million AUD | -737.7% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -1217.082% |
| Nyrada Inc. | -1.38 Million AUD | -2621.445% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 823.957% |
| Dimerix Limited | -17.07 Million AUD | -120.938% |
| PharmAust Limited | -9.03 Million AUD | -317.67% |
| AnteoTech Limited | -8.88 Million AUD | -324.811% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 35.681% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | -113.6% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -997.766% |
| Actinogen Medical Limited | -13.04 Million AUD | -189.21% |
| Immuron Limited | -6.93 Million AUD | -443.832% |
| Argenica Therapeutics Limited | -5.47 Million AUD | -588.484% |